EXPAREL Provides Pain Relief When It Matters Most
EXPAREL Delivers Effective Postsurgical Pain Management With Lasting Results
Can control postsurgical pain up to 96 hours1-6
Decreases opioid use*
Reduces the need for rescue pain
medications, supporting a faster
and more comfortable recovery
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
Clinically Proven Efficacy Across Five Pivotal Studies for Infiltration & Regional Blocks
EXPAREL vs Placebo in Bunionectomy
Significant Reduction in Pain Intensity Compared to Placebo for Up to 24 Hours
AUC, area under the curve.
EXPAREL vs Placebo in Hemorrhoidectomy6,7
Significantly
Lower Opioid Use*
45% lower overall opioid consumption (P=0.0006)*
Significantly
Better Pain Control†
30% lower cumulative pain scores (P<0.0001)
3 Out of 10 Patients Who Received EXPAREL Were Opioid-Free6
28%
with EXPAREL (n=95)
10%
with PLACEBO (n=94)
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
†Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio
AUC, area under the curve.
EXPAREL vs Placebo in ISBP Nerve Block for Total Shoulder Arthroplasty & Rotator Cuff Repair Study3*
78% Fewer
Opioids†
overall opioid consumption (P<0.0001)
Significantly
Better
Pain Control
cumulative pain scores (P<0.0001)
Significantly More Patients Were Opioid-Free With EXPAREL
23%
at 24 hours (P<0.0001)
13%
at 48 hours (P=0.008)
*Rescue opioids for pain were available upon patient request
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials AUC, area under the curve; ISBP, interscalene brachial plexus; VAS, visual analog scale.
EXPAREL vs Bupivacaine HCl in Foot & Ankle Surgery (Sciatic Nerve Block in the Popliteal Fossa Pivotal Trial)1
Superior Pain Control & Reduced Opioid Consumption Through 4 Days vs Bupivacaine HCl
Superior Pain Control vs Bupivacaine HCl
cumulative pain scores (P<0.00001)
61% Fewer
Opioids*
total postsurgical opioid consumption (P<0.00001)
5x More Participants Were Opioid-Free
through 4 days in the EXPAREL group
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
EXPAREL vs Bupivacaine HCl in TKA (Adductor Canal Pivotal Trial)2
Superior Pain Control & Reduced Opioid Consumption Through 4 Days vs Bupivacaine HCl
Superior Pain Control vs Bupivacaine HCl
cumulative pain scores (P<0.0074)
23% Fewer
Opioids*
total postsurgical opioid consumption (P<0.0071)
Significantly Better Pain Control vs Bupivacaine HCl Postsurgery On2,8:
Day 2
(P=0.0018)
Day 3
(P=0.0191)
Day 4
(P=0.0404)
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
Opioid concerns—addiction, dependency, and more pills—don’t have to be part of your patients’ recovery.9
EXPAREL provides a non-opioid alternative for effective pain management during the critical initial days after surgery.
